

**Patent claims:**

5

1. The use of active antithrombin III which has thrombin-inhibitory properties and affinity for heparin for the prophylaxis and treatment of disorders caused by angiogenesis or arteriogenesis.

10

2. The use as claimed in claim 1 of antithrombin III which contains active antithrombin for the prophylaxis and the treatment of disorders caused by angiogenesis or arteriogenesis.

15

3. The use of antithrombin III as claimed in claims 1 and 2, wherein the  $\alpha$  isoform, the  $\beta$  isoform, mixtures of the two or a concentrate of antithrombin III are used for the prophylaxis and the treatment of disorders 20 caused by angiogenesis or arteriogenesis.

25

4. The use of antithrombin III as claimed in claims 1 to 3, wherein it is employed for the prophylaxis and the treatment of retinopathies, neuropathies and infectious diseases such as leprosy.

30

5. The use of antithrombin as claimed in claims 1 to 3, wherein it is employed for the prophylaxis and treatment of cancerous ulcers and metastases of cancerous ulcers.

6. The use of antithrombin as claimed in claims 1 to 5, wherein it is administered intravenously, subcutaneously, intramuscularly or topically.

35

AVENTIS BEHRING